Treatment with Crexont statistically significantly improved “On” time without troublesome dyskinesia compared with carbidopa/levodopa IR. The Food and Drug Administration (FDA) has approved Crexont ® ...
The FDA issued a safety communication today warning of a potential increased risk of seizures tied to certain medications used to treat Parkinson's disease. The agency will require manufacturers of ...
The US Food and Drug Administration (FDA) has approved foscarbidopa and foslevodopa (Vyalev, AbbVie), a solution of carbidopa and levodopa prodrugs for 24-hour continuous subcutaneous infusion, for ...
Amneal to hold CREXONT launch symposium and scientific presentations at the International Congress of Parkinson’s Disease and Movement Disorders on Sept. 27 – Oct. 1, 2024 BRIDGEWATER, N.J.--(BUSINESS ...
If you have advanced Parkinson’s disease (PD), you may hear about a treatment option called Vyalev (foscarbidopa/foslevodopa). It was approved by the FDA in 2024 ...
Clinicians should monitor vitamin B6 levels in Parkinson disease patients taking carbidopa/levodopa due to a risk for deficiency-linked seizures. Reports of seizures linked to vitamin B6 deficiency in ...
Please provide your email address to receive an email when new articles are posted on . Once-daily opicapone 50 mg with carbidopa/levodopa helped achieve and maintain plasma concentrations of levodopa ...
The FDA approved a subcutaneous 24-hour continuous infusion of foscarbidopa and foslevodopa (Vyalev) for advanced Parkinson's disease, AbbVie announced Thursday. Foscarbidopa and foslevodopa are ...
The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use adopted a positive opinion for Onerji (levodopa/carbidopa, Tanabe Pharma) for the treatment of adults with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results